Commentary: The Management of Drug Expenditure Requires a Broad Perspective

Abstract

Get full access to this article

View all access options for this article.

References

1. Duval

Goldman

. The new drugs (chlorpromazine and reserpine): administrative aspects. Psychiatric Services 2000; 51: 327–331.

2. Emmerson

Estenson

Powell

Iwaniak

. Strategies to manage inpatient drug costs. Australasian Psychiatry 2001; 9: 249–252.

3. Geddes

Freemantle

Harrison

Bebbington

. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 2000; 321: 1371–1376.

4. Stannilard

Taylor

. Tolerabilty of atypical antipsychotics. Drug Safety 2000; 22: 195–214.

5. Marder

. Facilitating compliance with antipsychotic medication. Journal of Clinical Psychiatry 1998; 59(Suppl. 3)21–25.

6. Conley

Mahmoud

. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 2001; 158: 765–774.